Abstract
Among the more recent immunosuppressive agents, Sirolimus and monoclonal antibodies directed against the IL-2 receptor are the most promising. Sirolimus inhibits the G1-S phase of the cell cycle, at a later stage than calcineurin inhibitors, which interfere with the G0-G1 phase. Clinical studies have demonstrated the efficacy of Sirolimus in reducing the risk of rejection when combined with CsA and steroids. Sirolimus also proved to be effective as an alternative to CsA. The monoclonal antibodies directed against the IL-2 receptor significantly reduce the risk of acute rejection without side-effects. Other immunosuppressive agents are still being assessed in phase I-H clinical studies. FTY 720 may induce selective apoptosis of lymphocytes reacting against the donor's alloantigens. Antisense oligonucleotides interfere with adhesion molecules, while the monoclonal antibodies CTLA4-Ig and 5C-8 interfere with the co-stimulatory signals between the antigen presenting cell and the lymphocyte. An ever increasing number of new immunosuppressive agents is becoming available. The difficult task of the clinician is to find the right equilibrium in dosing and associating these new drugs in order to maximize the therapeutic effect of immunosuppressive treatment.
| Original language | Italian |
|---|---|
| Pages (from-to) | 180-185 |
| Number of pages | 6 |
| Journal | Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia |
| Volume | 16 |
| Issue number | 2 |
| Publication status | Published - 1999 |
Fingerprint
ASJC Scopus subject areas
- Nephrology
Cite this
Nuovi agenti immunosoppressori nel trapianto. / Ponticelli, C.; Montagnino, G.
In: Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, Vol. 16, No. 2, 1999, p. 180-185.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nuovi agenti immunosoppressori nel trapianto
AU - Ponticelli, C.
AU - Montagnino, G.
PY - 1999
Y1 - 1999
N2 - Among the more recent immunosuppressive agents, Sirolimus and monoclonal antibodies directed against the IL-2 receptor are the most promising. Sirolimus inhibits the G1-S phase of the cell cycle, at a later stage than calcineurin inhibitors, which interfere with the G0-G1 phase. Clinical studies have demonstrated the efficacy of Sirolimus in reducing the risk of rejection when combined with CsA and steroids. Sirolimus also proved to be effective as an alternative to CsA. The monoclonal antibodies directed against the IL-2 receptor significantly reduce the risk of acute rejection without side-effects. Other immunosuppressive agents are still being assessed in phase I-H clinical studies. FTY 720 may induce selective apoptosis of lymphocytes reacting against the donor's alloantigens. Antisense oligonucleotides interfere with adhesion molecules, while the monoclonal antibodies CTLA4-Ig and 5C-8 interfere with the co-stimulatory signals between the antigen presenting cell and the lymphocyte. An ever increasing number of new immunosuppressive agents is becoming available. The difficult task of the clinician is to find the right equilibrium in dosing and associating these new drugs in order to maximize the therapeutic effect of immunosuppressive treatment.
AB - Among the more recent immunosuppressive agents, Sirolimus and monoclonal antibodies directed against the IL-2 receptor are the most promising. Sirolimus inhibits the G1-S phase of the cell cycle, at a later stage than calcineurin inhibitors, which interfere with the G0-G1 phase. Clinical studies have demonstrated the efficacy of Sirolimus in reducing the risk of rejection when combined with CsA and steroids. Sirolimus also proved to be effective as an alternative to CsA. The monoclonal antibodies directed against the IL-2 receptor significantly reduce the risk of acute rejection without side-effects. Other immunosuppressive agents are still being assessed in phase I-H clinical studies. FTY 720 may induce selective apoptosis of lymphocytes reacting against the donor's alloantigens. Antisense oligonucleotides interfere with adhesion molecules, while the monoclonal antibodies CTLA4-Ig and 5C-8 interfere with the co-stimulatory signals between the antigen presenting cell and the lymphocyte. An ever increasing number of new immunosuppressive agents is becoming available. The difficult task of the clinician is to find the right equilibrium in dosing and associating these new drugs in order to maximize the therapeutic effect of immunosuppressive treatment.
KW - Anti-IL-2 antibodies
KW - Antisense oligonucleotides
KW - Clinical trials
KW - CTLA 4-Ig
KW - FTY 720
KW - Gusperimus
KW - RAD
KW - Renal transplantation
KW - Sirolimus
UR - http://www.scopus.com/inward/record.url?scp=0032701841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032701841&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0032701841
VL - 16
SP - 180
EP - 185
JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
SN - 0393-5590
IS - 2
ER -